mRNA Vaccine, Plus Pembrolizumab, Minimizes Recurrence Rate in Melanoma
Combined adjuvant treatment with mRNA-4157 in combination with pembrolizumab improved recurrence rates in patients with resected high-risk melanoma.
Second-Line Options Expand With the Use of Immunotherapy in Advanced Endometrial Cancer
Oncology nurse experts review their experiences with newcomers for the treatment of advanced endometrial cancer and exchange best practices in caring for this population.
Mirvetuximab Soravtansine Offers New Path Forward for Patients with Frα-Positive Platinum-Resistant Ovarian Cancer
Kathleen Lutz, RN, NP-BC WH, weighs in on the recent approval of mirvetuximab soravtansine-gynx for patients with folate receptor alpha (Frα)-positive, platinum-resistant ovarian cancer.
Adagrasib Demonstrates CNS Activity in KRAS G12C+ NSCLC
The intracranial objective response rate was 32% among patients with KRAS G12C–mutant, non–small cell lung cancer who received adagrasib.
Checkpoint Blockade Drives Progress in Endometrial Cancer Treatment
An expert from NYU Langone outlines how checkpoint blockade approvals have helped advance endometrial cancer management.
Oncology Nurse Champion: Kathleen Lutz
From orchestrating local infusion appointments to making lunch for a patient, Kathleen Lutz, RN, NP-BC WH, constantly strives to provide an excellent level of supportive care.
New MPN Treatments Improve Survival and Symptom Burden
Combinations of JAK inhibitors and novel agents, such as epigenetic regulators, could help prolong survival in patients with myeloproliferative neoplasms.
How To Choose Immunotherapy or BRAF-Targeted Treatment for Adjuvant Melanoma
There is still a great deal to learn about the optimal use of BRAF-targeted therapy, as well as immunotherapy, in the adjuvant setting for patients with melanoma.
Neoadjuvant Durvalumab Combination Misses Mark in EGFR+ NSCLC
Durvalumab Garners Similar OS, Albeit Varied PFS, Outcomes in EGFR+ and EGFR-Wildtype NSCLC Subgroups
Quizartinib Extends Overall Survival Across Multiple Subgroups in FLT3-ITD+ AML
Repotrectinib Showcases Early Intracranial Responses in Select ROS1+ NSCLC
